Versigent Q2 FY26 net income rises 10.3% to $118 million; net sales increase 10.8% to $2.44 billion
Reuters2026/08/04 10:49- Versigent Q2 2026 net sales rose 10.8% to $2.44 billion; net income attributable to shareholders increased 10.3% to $118 million.
- Diluted EPS climbed to $1.64; interest expense widened to $36 million from $1 million a year earlier.
- Free cash flow held at $107 million; operating cash flow edged up to $158 million from $150 million.
- Board declared an inaugural quarterly dividend of $0.13 per share, payable Sept. 18 to holders of record Sept. 4.
- Lifted full-year net sales outlook to $9.4 billion-$9.6 billion from $9.1 billion-$9.4 billion; reaffirmed adjusted EBITDA of $950 million-$1.03 billion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
